Pull to refresh
Logo
Daily Brief
Following Why Sign Up
Ryan Watts

Ryan Watts

Chief Executive Officer, Denali Therapeutics

Appears in 1 story

Notable Quotes

"We believe that solving brain delivery is the single most important technical challenge in neuroscience drug development." — Ryan Watts, public presentations

Stories

First drug engineered to cross the blood-brain barrier wins FDA approval

New Capabilities

Leading commercial launch of AVLAYAH

For decades, the blood-brain barrier has blocked nearly all large-molecule drugs from reaching the brain — a biological wall that left most neurological diseases effectively untreatable with modern biologics. On March 25, 2026, the Food and Drug Administration (FDA) approved AVLAYAH, developed by Denali Therapeutics, making it the first drug in history specifically engineered to cross that barrier and deliver a therapeutic enzyme to the central nervous system after a simple intravenous infusion.

Updated 4 hours ago